Blood

1. CROMBIE JL, Redd R, Phinney C, Forsyth M, et al
   A multicenter phase II study of glofitamab plus polatuzumab-R-CHP for patients with diffuse large B-cell lymphoma.
   Blood. 2026 Oct 6:blood.2026034588. doi: 10.1182/blood.2026034588.
   

   >> Share

   
   
2. OLSZEWSKI AJ, Eradat HA, Avigdor A, Horowitz NA, et al
   Mosunetuzumab and Polatuzumab Vedotin as First-line Treatment for Large B Cell Lymphoma in Older Unfit or Frail Patients.
   Blood. 2026 Oct 5:blood.2026035116. doi: 10.1182/blood.2026035116.
   

   >> Share

   
   
3. BORRY R, Vilcot F, Tesson B, Moraly J, et al
   STAG2 mutations fine-tune the ALK-driven oncogenic program in ALK-positive anaplastic large cell lymphoma.
   Blood. 2026 Oct 5:blood.2025032902. doi: 10.1182/blood.2025032902.
   

   >> Share

   
   

   
   Bone Marrow Transplant

4. PAVIGLIANITI A, Fekom M, Halahleh K, Benakli M, et al
   BEAM versus EAM, FEAM, BeEAM, and TEAM: exploring conditioning strategies in autologous stem cell transplantation for Hodgkin lymphoma a retrospective study of the LWP of EBMT.
   Bone Marrow Transplant. 2026 Oct 6. doi: 10.1038/s41409-026-03043.
   

   >> Share

   
   

   
   Haematologica

5. GIORDANO C, Picardi M
   Preserving anthracycline-containing treatment in older patients with classical Hodgkin lymphoma: a role for liposomal doxorubicin. Comment on: "Age, anthracycline and mortality in 28,000 classic Hodgkin lymphoma patients: cohort study of a complete po
   Haematologica. 2026 Oct 8. doi: 10.3324/haematol.2026.302077.
   

   >> Share

   
   
6. MERIRANTA L, Arffman M, Autio M, Jorgensen J, et al
   Molecular surveillance of aggressive large B-cell lymphoma using circulating tumor DNA duplexes.
   Haematologica. 2026 Oct 8. doi: 10.3324/haematol.2026.301093.
   

   >> Share

   
   
7. DAVIDS MS, Ambrose J, De Nigris E, Prescott J, et al
   Real-world treatment patterns and outcomes in patients with chronic lymphocytic leukemia previously exposed to both covalent Bruton's tyrosine kinase inhibitor and B-cell lymphoma 2 inhibitor therapy.
   Haematologica. 2026 Oct 8. doi: 10.3324/haematol.2026.300690.
   

   >> Share

   
   
8. TORKA P, Bock AM, Hao P, Xu Y, et al
   Nivolumab with doxorubicin, vinblastine, and dacarbazine in older adults with classic Hodgkin lymphoma: do S1826 results hold up in the real world?
   Haematologica. 2026 Oct 8. doi: 10.3324/haematol.2026.301545.
   

   >> Share

   
   

   
   Leuk Lymphoma

9. TURUNEN A, Kuittinen O, Varmavuo V, Jantunen E, et al
   Delayed platelet recovery in lymphoma patients after autologous hematopoietic cell transplantation - risk factors and prognostic significance.
   Leuk Lymphoma. 2026 Oct 7:1-5. doi: 10.1080/10428194.2026.2738355.
   

   >> Share

   
   
10. QUON S, Lum-Wang S, Ingledew PA
    Evaluating YouTube videos for Hodgkin lymphoma patient education.
    Leuk Lymphoma. 2026 Oct 5:1-7. doi: 10.1080/10428194.2026.2741486.
    

    >> Share

    
    

    
    Oncogene

11. YOKOYAMA K, Chiba M, Takei N, Suto K, et al
    Genome-wide CRISPR screens identify an RXR-MYLIP-LDLR axis regulating BH3 mimetic sensitivity in peripheral T-cell lymphomas.
    Oncogene. 2026;45:4393-4405.
    

    >> Share

    
    

    
    PLoS One

12. MARTINEZ ALCALA R, Visser L, Fortpied C, Ferme C, et al
    Immunohistochemistry for c-MET, HLA class II, and CD68 does not show prognostic value in early-stage classic Hodgkin lymphoma patients in the EORTC-GELA H9 intergroup randomised trial.
    PLoS One. 2026;21:e0360080.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share